Last mentioned: Feb 27, 2026
EU Expansion
Positive CHMP opinion received, enabling commercialization in the European Union.
Public Offering
Crinetics raises capital, bringing total cash position to $1.4 billion.
Q4 Milestone
Over 200 enrollment forms and 125 unique prescribers recorded for Palsonify.
Palsonify Launch
Crinetics initiates U.S. commercial launch of Palsonify for acromegaly.
Q4 2025 earnings reports highlight a strategic shift toward AI-integrated hardware and high-margin services, with Aeva securing a pivotal NVIDIA partnership and Arlo achieving record SaaS metrics. Meanwhile, Crinetics successfully launched Palsonify, backed by a massive $1.4 billion cash reserve to fuel global expansion.
This page surfaces every story mentioning Crinetics Pharmaceuticals across our ai coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running ai beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Crinetics Pharmaceuticals was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |